BARD Score for NAFLD Fibrosis

Loading...

References

  1. NA. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).. Journal of hepatology, 2024
  2. Julia J Wattacheril. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.. Gastroenterology, 2023
  3. Yasaman Vali. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.. The lancet. Gastroenterology & hepatology, 2023
  4. NA. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.. Journal of hepatology, 2021
  5. H. Hagström. Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.. Gastroenterology, 2019
  6. Guangqin Xiao. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis. Hepatology, 2017
  7. P. Angulo. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.. Gastroenterology, 2013
  8. Stuart McPherson. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 2010
  9. S. Harrison. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut, 2008